Published: 19 October 2022
Author(s): Irene Cecchi, Massimo Radin, Silvia Grazietta Foddai, Marta Arbrile, Alice Barinotti, Elena Rubini, Alessandro Morotti, Vittorio Pengo, Dario Roccatello, Savino Sciascia
Issue: January 2023
Section: Review Article

Antiphospholipid syndrome (APS) is an autoimmune condition characterized by thrombosis (arterial, venous, and microvascular) and/or pregnancy morbidity occurring in subjects persistently positive for antiphospholipid antibodies (aPL). Current laboratory classification criteria for APS include the presence of lupus anticoagulant (LA), anticardiolipin (aCL), or anti-β2-glycoprotein I antibodies (aß2GPI) tested positive on two separate occasions at least 12 weeks apart [1]. While the APS classification criteria are being currently updated to improve homogeneity in clinical research [2], patients who seek medical treatment often have a variety of laboratory and/or clinical characteristics that may not completely encompass the classification criteria for overt APS.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.